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In vitro modeling of hepatocellular carcinoma
molecular subtypes for anti-cancer drug assessment
Hadassa Hirschﬁeld1, C Billie Bian1, Takaaki Higashi1,2, Shigeki Nakagawa1,2, Tizita Z Zeleke1,
Venugopalan D Nair3, Bryan C Fuchs4 and Yujin Hoshida1
Tractable experimental model that accounts for inter-tumor molecular heterogeneity is a key element of anti-cancer drug
development. Hepatocellular carcinoma is known to exhibit highly heterogeneous molecular aberrations across the tumors,
including somatic genetic and epigenetic alterations. Previous studies showed that molecular tumor subtypes determined by
transcriptome, as a comprehensive functional readout, are reproducibly observed across global patient populations irrespective of
geographic and etiological variations. Here we demonstrate that transcriptomic hepatocellular carcinoma subtypes, S1 and S2,
determined by our previous transcriptome meta-analysis of multiple clinical hepatocellular carcinoma cohorts, are presented in a
panel of hepatoma cell lines widely used by the research community. Interestingly, cell line that resembles gene expression
pattern of S3 subtype, representing less aggressive tumors, was not identiﬁed in the panel. MYC pathway-activated S2-like cell
lines showed higher sensitivity to a small molecule BET bromodomain inhibitor, (+)-JQ1, which has anti-MYC activity. These
results support the use of hepatoma cell lines as models to evaluate molecular subtype-speciﬁc drug response, which is
expected to lead to development of tailored, precision care of the patients with hepatocellular carcinoma.
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INTRODUCTION
Experimental models are key components of anti-cancer drug
development and an urgent unmet need for hepatocellular
carcinoma (HCC), which still lacks substantially effective
medical therapy.1 Extensive genomic analysis of HCC tumors
has clariﬁed signiﬁcant inter- and intra-tumor molecular
heterogeneity, which likely obscures therapeutic effect of
molecular targeted agents. Potentially druggable somatic
DNA mutations are generally rare (prevalence o5%), which
makes patient enrollment in clinical trials more challenging.2
A recent study of patient-derived HCC cell lines demonstrated
selective killing only in subclones that harbor the relatively
rare somatic DNA aberrations such as FGF19 gene
ampliﬁcation.3
Transcriptome is an alternative measure, which is assumed
to be functional readouts of various types of molecular
aberrations such as mutations and epigenetic changes.
Our previous transcriptome meta-analysis revealed three sub-
types, namely S1, S2 and S3, which are observed in larger
fractions of patients/tumors (prevalence420%) associated with
speciﬁc molecular pathway dysregulation and patient
prognosis.1,4,5 The subtypes are associated with clinical
characteristics such as serum α-fetoprotein (AFP) levels, and
also with histological intra-tumor heterogeneity, suggesting
their clinical relevance.5 It is empirically known that some of
the transcriptomic subtypes are present in human hepatoma
cell lines, with which subtype-speciﬁc in vitro and in vivo
anti-cancer drug response has been demonstrated.6–8 In
parallel, clinical features associated with the subtypes such as
AFP (a marker of the S2 subtype) have been recognized as
possible predictive biomarkers of therapeutic response to
molecular targeted agents as shown in recent clinical trials.9
These ﬁndings collectively suggest that hepatoma cell lines can
be used as tractable and clinically relevant experimental
models of the HCC subtypes for assessment of molecular
targeted anti-cancer agents. In this study, we have
systematically evaluated the HCC subtypes and their
association with therapeutic response in a panel of frequently
and widely used hepatoma cell lines.
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MATERIALS AND METHODS
Transcriptomic subtyping of hepatoma cell lines
Pre-normalized genome-wide transcriptome and DNA mutation
data sets of 25 hepatoma cell lines (Table 1) were downloaded
from the Cancer Cell Line Encyclopedia (CCLE) website (https://
portals.broadinstitute.org/ccle/home). Pre-normalized genome-wide
transcriptome data set of 374 human HCC tissues was downloaded
from The Cancer Genome Atlas (TCGA) website (https://gdc.cancer.
gov). In the CCLE hepatoma data set, transcriptome proﬁle of PLC/
PRF/5 cell line duplicated in an alternative name (Alexander) was
excluded. Hepatoblastoma-derived cell lines, Hep G2 and its derivative
C3A,10 and undifferentiated hepatoma cell lines, HLE and HLF, were
included in the analysis given their wide use in the HCC research
community. Transcriptomic subtyping of the cell lines was performed
based on the HCC subtype maker gene signatures by using the Nearest
Template Prediction algorithm as previously reported.4,11 Non-
negative matrix factorization (NMF)-based consensus clustering was
used to explore optimal number of classes in the global transcriptome
data set after excluding less variable probes based on a coefﬁcient of
variation (CV) cutoff of 0.5.12
Cell lines
SNU-182, SNU-387, SNU-475, SNU-449, Hep G2, Hep 3B2.1-7,
Huh-7 and THLE-5B cells (American Type Culture Collection or
Riken Bioresource, Japan) were grown in DMEM supplemented with
10% heat-inactivated fetal bovine serum, 100 U ml− 1 penicillin
(Gibco, Gaithersburg, MD, USA) and 100 μg ml− 1 streptomycin
(Gibco) at 37 °C in a 5% CO2 atmosphere.
HCC subtyping with NanoString assay
Total RNA was extracted from the cell lines using RNeasy kit (Qiagen,
Germantown, MD, USA), and 200 ng total RNA was subjected to the
Elements HCC subtyping assay (NanoString, Seattle, WA, USA) as
previously reported.5 Raw transcript count data were normalized by
scaling with geometric mean of built-in normalization genes. HCC
subtype determination was similarly performed by the Nearest
Template Prediction algorithm.
In vitro anti-HCC drug treatment
A total of 3000–5000 cells were plated in each well in 96-well plates
according to growth rate of each cell line, and when 50% conﬂuence
was reached ~ 24 h later, treatment with (+)-JQ1 (Selleckchem,
Houston, TX, USA) at varying concentrations was started and
continued for 48 h in triplicates.
Cell viability analysis
Cell viability was assessed using an MTS Cell Proliferation Assay
(Promega, Madison, WI, USA). A volume of 22 μl of the MTS assay
solution was added to each well that contained 110 μl of media. The
plates were then incubated at 37 °C in a 5% CO2 atmosphere for 4 h.
The absorbance was then read at 490 nm. Averaged absorbance from
Table 1 Characteristics of 25 hepatoma cell lines
Cell line Histological type HBV HCV AFP DCP Race Age Sex Source ID Reference
Hep 3B2.1-7 HCC (+) NA (+) (+) Black 8 M ATCC HB-8064 29
huH-1 HCC (+) NA (+) NA Asian 53 M JCRB JCRB0199 30
Huh-7 HCC (− ) NA (+) NA Asian 57 M RIKEN RCB, JCRB RCB1366, JCRB0403 30
JHH-1 HCC (− ) NA (+) NA Asian 50 M JCRB JCRB1062 31
JHH-2 HCC (− ) NA (+) NA Asian 57 M JCRB JCRB1028 31
JHH-4 HCC (− ) NA (+) NA Asian 51 M JCRB JCRB0435 32
JHH-5 HCC (− ) NA (+) NA Asian 50 M JCRB JCRB1029 31
JHH-6 HCC (− ) NA (− ) NA Asian 57 F JCRB JCRB1030 31
JHH-7 HCC (+) NA (+) NA Asian 53 M JCRB JCRB1031 33
Li-7 HCC (− ) (− ) (+) NA Asian 45 M RIKEN RBC RCB1941 —
PLC/PRF/5 HCC (+) NA (+) (+) Black 24 M ATCC, JCRB CRL-8024, JCRB0406 34
SK-HEP-1 HCC (− ) NA (− ) (− ) White 52 M ATCC HTB-52 —
SNU-182 HCC (+) NA (− ) NA Asian 24 M ATCC CRL-2235 35
SNU-387 HCC (+) NA (− ) NA Asian 41 F ATCC CRL-2237 35
SNU-398 HCC (+) NA (− ) NA Asian 42 M ATCC CRL-2233 35
SNU-423 HCC (+) NA (− ) NA Asian 40 M ATCC CRL-2238 35
SNU-449 HCC (+) NA (− ) NA Asian 52 M ATCC CRL-2234 35
SNU-475 HCC (+) NA (− ) NA Asian 43 M ATCC CRL-2236 35
SNU-761 HCC (+) NA (+) NA Asian 49 M KCLB KCLB00761 36
SNU-878 HCC (+) NA (− ) NA Asian 54 F KCLB KCLB00878 36
SNU-886 HCC (+) NA (+) NA Asian 57 M KCLB KCLB00886 36
Hep G2 Hepatoblastoma (− ) (− ) (+) NA White 15 M ATCC, JCRB HB-8065, JCRB1054 —
C3A Hepatoblastoma (− ) (− ) (+) NA White 15 M ATCC CRL-10741 —
HLE Undifferentiated hepatoma (− ) NA (− ) NA Unknown 68 M JCRB JCRB0404 37
HLF Undifferentiated hepatoma (− ) NA (− ) NA Unknown 68 M JCRB JCRB0405 37
Abbreviations: AFP, α-fetoprotein; DCP, des-gamma-carboxy prothrombin; ATCC, American Type Culture Collection (https://www.atcc.org); HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; HCV: hepatitis C virus; JCRB, Japanese Collection of Research Bioresources (http://cellbank.nibiohn.go.jp/english); KCLB, Korean Cell Line
Bank (http://cellbank.snu.ac.kr/english); NA, not applicable; RIKEN BRC: RIKEN Bioresource Center (http://en.brc.riken.jp/index.shtml).
In vitro modeling of hepatocellular carcinoma
H Hirschﬁeld et al
2
Experimental & Molecular Medicine
empty wells was subtracted from all wells as background signal, and
relative cell viability was calculated as a percentage of the adjusted
absorbance compared to respective DMSO-treated control wells.
Statistical analysis
Proportion of categorical data was assessed by Fisher’s exact test.
Two-tailed P-value o0.05 was regarded as statistically signiﬁcant. All
analyses were performed using R statistical language (www.r-project.
org).
RESULTS
Transcriptomic subtyping of hepatoma cell lines
Our previous transcriptome meta-analysis involving 603
clinical HCC tissues revealed the following three subtypes:
S1 subtype characterized by activation of stromal gene/pathway
such as transforming growth factor β (TGFβ), S2 subtype
with overexpression of stemness markers such as EPCAM and
AFP, and S3 subtype enriched with more differentiated tumors
and accumulation of CTNNB1 exon 3 mutations associated
with induction of liver-speciﬁc Wnt pathway target, GLUL.13
It has been reported that hepatoma cell lines are classiﬁed
into two groups by unsupervised clustering of global
transcriptome proﬁles, which is correlated with AFP expression
status.14,15 AFP-high and -low cell lines were empirically
known to exhibit transcriptome proﬁles similar to S2 and S1
subtypes, respectively.4 Consistent with these observations,
non-negative matrix factorization consensus clustering of
the genome-wide transcriptome proﬁles of 25 hepatoma
cell lines from the CCLE data set revealed that optimal
classiﬁcation is indeed achieved when two subclasses are
assumed (Figure 1a). In the surgically resected clinical HCC
tissues (n= 374), median expression levels of each HCC
subtype marker genes in each sample (S1: 238 genes, S2: 115
genes and S3: 266 genes) depicted relative abundance of each
subtype marker gene expression in human HCC tissues
(Figure 1b).
In the hepatoma cell lines, the relative expression levels of
the S1 and S2 subtype marker genes were maintained, whereas
the S3 subtype marker genes were not expressed at the levels in
tissues, suggesting that the hepatoma cell lines generally lack
characteristic of the S3 subtype. In fact, the CTNNB1 exon 3
mutations prevalent in the S3 subtype, was observed only in
one cell lines (SNU-398) with relatively low expression of
the target gene GLUL (Figures 1c and 2). These results
collectively support that the hepatoma cell lines are classiﬁed
into either the S1 or S2 subtype, and there is no cell line
corresponding to the S3 subtype. In contrast, TP53 gene
mutations were more frequently observed (12 out of 22 cell
lines with mutation data, 55%) as seen in clinical tissues, and
Figure 1 Transcriptomic hepatocellular carcinoma (HCC) subtypes and DNA mutations in 25 hepatoma cell lines. (a) Optimal number of
unsupervised subclasses in the global transcriptome proﬁles of the 25 hepatoma cell lines from the Cancer Cell Line Encyclopedia (CCLE)
data set was determined by cophenetic coefﬁcient from non-negative matrix factorization (NMF) consensus clustering for each assumed
number of subclasses, ranging from 2 to 5. (b) Median expression levels of the HCC subtype marker genes across the samples are plotted
for each subtype in 374 clinical HCC tissues (left) and 25 hepatoma cell lines (right). Boxes represent 75th and 25th percentile,
horizontal line is the median, and whiskers mark lowest and highest values. Outliers outside 1.5× of inter-quartile range are shown as
open circles. (c) GLUL expression level in the 25 hepatoma cell lines. Arrow head indicates a cell line with CTNNB1 exon 3 mutation.
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HIF1A was the most frequently affected gene by mutations
(68%). Prevalence of these mutations was similar between the
HCC subtypes for TP53 (P= 0.67, Fisher’s exact test), HIF1A
(P= 0.38), TERT promoter (P= 1.0) and rest of the genes
recurrently affected in human HCC tissues (P= 0.83).2
Transcriptomic subtyping of hepatoma cells by an
FDA-approved assay
We have implemented a reduced version of the HCC subtyping
gene signature (30-gene signature) in an FDA-approved
diagnostic assay platform (NanoString) for clinical application
in our previous study.5 The HCC subtype determination
based on the genome-wide transcriptome data (Figure 2) was
veriﬁed by using the NanoString assay for six representative
hepatoma cell lines (SNU-465, SNU-449, SNU-387, Huh-7,
Hep 3B and Hep G2) together with the non-tumorigenic
SV40-immortalized hepatocyte line, THLE-5B.16 The relative
expression of subtype S1 and S2 marker genes as well as low
expression of S3 marker genes was veriﬁed in the hepatoma
cells, and a similar pattern was observed in THLE-5B cells
(Figure 3a). This result suggests that the lower expression of the
S3 marker genes compared to HCC tissues is a common
feature in established cell lines irrespective of origin, that
is, malignant or non-malignant cells. The HCC subtype
determination was also conﬁrmed in the 30-gene HCC
subtyping assay, supporting validity of the assay (Figure 3b).
HCC subtypes are associated with response to molecular
targeted agents
In our previous study, we could successfully demonstrate
in vitro and in vivo subtype-speciﬁc drug response by targeting
ﬁbroblast growth factor receptor pathway, one of the molecular
hallmarks speciﬁcally activated in the S2 subtype.8 We sought
to extend this examination to another pathway implicated
in HCC subtypes. MYC pathway is known to be activated in
the S2 subtype.4 Direct targeting of this pathway has been
technically challenging, but BET bromodomain inhibition by a
small molecule, (+)-JQ1 has been show to elicit anti-MYC
pathway activity.17,18 To evaluate whether the subtype-
dependent response to MYC pathway inhibition can be
monitored in hepatoma cells, SNU-387 and SNU-182 (S1-like
cells) as well as Huh-7 and Hep G2 (S2-like cells) were treated
with (+)-JQ1. In the CCLE data set, expression of the target
genes, BRD2, BRD3 or BRD4, at naive state was conﬁrmed in
Figure 2 Transcriptomic hepatocellular carcinoma (HCC) subtypes and DNA mutations in 25 hepatoma cell lines. HCC subtypes were
determined using genome-wide transcriptome data by the Nearest Template Prediction (NTP) algorithm as previously described.4
Expression pattern of the HCC subtype marker genes is shown in the heatmap.
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the S2-like cell lines, which are already known to exhibit MYC
pathway activation (Figure 4a).4 As expected, the S2-like cell
lines showed higher sensitivity to (+)-JQ1 as indicated by lower
half maximal inhibitory concentration (IC50) values
(Figure 4b), further supporting the use of hepatoma cell lines
as experimental models to assess molecular subtype-speciﬁc
anti-HCC drug response.
DISCUSSION
This study provides comprehensive reference information for a
panel of widely used and commercially available hepatoma cell
lines as in vitro models of human HCC molecular subtypes.
Alternative strategies such as patient-derived xenograft (PDX)
could enable personalized molecular evaluation for each
patient.19 However, the low success rate and long time required
to establish viable lines limit their ﬂexible use. In contrast,
despite the well-recognized limitations such as lacked tissue
architecture and crosstalk with other cell types, cancer cell lines
remain one of the major experimental models for anti-cancer
drug discovery and assessment as a tractable system easily
amenable to high-throughput and high-content molecular
analysis.20,21
Modeling of speciﬁc disease contexts such as clinical/
molecular tumor subtypes is generally attempted by genetic
Figure 3 Transcriptomic hepatocellular carcinoma (HCC) subtypes determined by the NanoString assay. (a) Median expression levels of the
HCC subtype marker genes are plotted for each subtype in seven cell lines. Red dots indicate expression in THLE-5B cells. Boxes
represent 75th and 25th percentile, horizontal line is the median, and whiskers mark lowest and highest values. Outliers outside 1.5× of
inter-quartile range are shown as open circles. (b) Expression pattern of the HCC subtype marker genes in the seven cell lines is shown in
the heatmap.
Figure 4 Transcriptomic hepatocellular carcinoma (HCC) subtype-dependent drug response in hepatoma cell lines. (a) Expression of BRD2,
BRD3 and BRD4 genes, encoding targets of a BET bromodomain inhibitor, (+)-JQ1, in the S1-like (SNU-387 and SNU-182) and S2-like
(Huh-7 and Hep G2) hepatoma cell lines in the CCLE data set. (b) Relative cell viability compared to DMSO-treated controls after 48 h
treatment with (+)-JQ1 in a series of drug concentrations (range: 0.01–13.6 μM).
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engineering in experimental systems. However, it is practically
infeasible to reconstitute the full spectrum of complex
genetic and epigenetic molecular aberrations generally observed
in non-hereditary solid cancers. Our study highlights an
advantage of using existing hepatoma cell lines that inherently
exhibit and recapitulate naturally occurring transcriptomic
dysregulation observed in two of the three consensus human
HCC molecular subtypes, which represent more advanced and
aggressive tumors and therefore should be prioritized for
therapeutic development. In fact, multiple preclinical studies
and clinical trials support this concept. Dasatinib (Src/Abl
inhibitor) was more effective in the S1-like cells.6 S2-like cells
were more susceptible to epidermal growth factor receptor
(EGFR) and insulin-like growth factor 1 receptor (IGF1R)
inhibition.22,23 BGJ398 (pan-ﬁbroblast growth factor receptor
inhibitor) elicited in vivo anti-tumor effect in xenograft of the
S2-like cells.8 Epitope-optimized genetic vaccines targeting AFP
(S2 marker)-induced speciﬁc CD8 T-cell-mediated killing of
HCC cells in mice.24 Galunisertib, which targets the TGFβ
pathway, a hallmark of the S1 subtype, is currently under
evaluation in a phase 2 trial (ClinicalTrials.gov,
NCT01246986).25 Tivantinib (MET inhibitor),26 ramucirumab
(VEGFR2 inhibitor, showed better response in AFP-high
patients)9 and GC33 (humanized monoclonal antibody
against glypican 3 [GPC3])27,28 were tested in clinical trials
and could be more effective in the S2 subtype.
In our analysis of 25 hepatoma cell lines and one
immortalized hepatocyte line, we could not ﬁnd any cell line
with the features of the S3 subtype. This may indicate that
HCC cells in S3 tumors, clinically more differentiated
and associated with better prognosis, are not capable of
survival and proliferation in culture without support from
the physiological liver tissue architecture. It is important to
note that there is certain diversity in the characteristic
molecular features for each subtype between the cell lines.
Therefore, presence or absence of speciﬁc features (for
example, AFP secretion status), which are potentially relevant
to mechanism of action for agents to be tested, must be
conﬁrmed before picking cell lines for evaluation. In addition,
differences in the sources and/or passages could alter the
status of transcriptomic subtypes and other genetic aberrations,
which ideally should be veriﬁed prior to the assessment. In
summary, noting these limitations, hepatoma cell lines with
designated HCC subtypes represent an invaluable resource as
experimental models that retain the intra/inter-tumor/patient
heterogeneity for anti-cancer drug assessment and
development.
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